Equities research analysts expect that Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) will announce sales of $9.47 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Nabriva Therapeutics’ earnings. The lowest sales estimate is $8.53 million and the highest is $10.40 million. Nabriva Therapeutics posted sales of $8.24 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 14.9%. The company is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Nabriva Therapeutics will report full-year sales of $41.31 million for the current year, with estimates ranging from $39.32 million to $43.29 million. For the next financial year, analysts expect that the firm will report sales of $71.73 million, with estimates ranging from $67.25 million to $76.21 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Nabriva Therapeutics had a negative return on equity of 82.07% and a negative net margin of 137.52%. During the same period in the previous year, the company earned ($0.53) earnings per share.
NBRV stock opened at $0.19 on Wednesday. Nabriva Therapeutics has a 1 year low of $0.18 and a 1 year high of $2.32. The stock has a 50-day simple moving average of $0.34 and a 200-day simple moving average of $0.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.94 and a current ratio of 4.01. The firm has a market cap of $120.59 million, a P/E ratio of -0.20 and a beta of 1.57.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Holdings Inc. lifted its position in shares of Nabriva Therapeutics by 5,200.0% in the third quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 26,000 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Nabriva Therapeutics in the second quarter worth approximately $42,000. Two Sigma Securities LLC purchased a new stake in shares of Nabriva Therapeutics in the third quarter worth approximately $48,000. Geode Capital Management LLC lifted its position in shares of Nabriva Therapeutics by 102.9% in the third quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 21,672 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Nabriva Therapeutics in the fourth quarter worth approximately $125,000. Institutional investors own 1.55% of the company’s stock.
Nabriva Therapeutics Company Profile (Get Rating)
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- 3 Defensive Consumer Stocks Worth Shopping For
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.